Syneos Health Valuation

Is SYNH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SYNH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SYNH ($42.98) is trading below our estimate of fair value ($57.57)

Significantly Below Fair Value: SYNH is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SYNH?

Other financial metrics that can be useful for relative valuation.

SYNH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.3x
Enterprise Value/EBITDA12.4x
PEG Ratio1.9x

Price to Earnings Ratio vs Peers

How does SYNH's PE Ratio compare to its peers?

The above table shows the PE ratio for SYNH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average49.4x
SHC Sotera Health
65.7x40.3%US$3.4b
STVN Stevanato Group
55.3x14.5%US$8.7b
TECH Bio-Techne
48.7x9.9%US$10.9b
QGEN Qiagen
27.7x11.2%US$9.5b
SYNH Syneos Health
62.6x33.7%US$4.5b

Price-To-Earnings vs Peers: SYNH is expensive based on its Price-To-Earnings Ratio (62.6x) compared to the peer average (29x).


Price to Earnings Ratio vs Industry

How does SYNH's PE Ratio compare vs other companies in the US Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.3%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.3%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: SYNH is expensive based on its Price-To-Earnings Ratio (62.6x) compared to the US Life Sciences industry average (35.4x).


Price to Earnings Ratio vs Fair Ratio

What is SYNH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SYNH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio62.6x
Fair PE Ratio29.8x

Price-To-Earnings vs Fair Ratio: SYNH is expensive based on its Price-To-Earnings Ratio (62.6x) compared to the estimated Fair Price-To-Earnings Ratio (29.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SYNH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
Mar ’25n/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
Feb ’25n/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
Jan ’25n/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
Dec ’24n/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
Nov ’24n/a
US$42.63
0%
2.3%US$43.00US$40.00n/a8
Oct ’24US$42.98
US$42.63
-0.8%
2.3%US$43.00US$40.00n/a8
Sep ’24US$42.72
US$42.67
-0.1%
2.2%US$43.00US$40.00n/a9
Aug ’24US$42.36
US$42.70
+0.8%
2.1%US$43.00US$40.00n/a10
Jul ’24US$42.14
US$42.70
+1.3%
2.1%US$43.00US$40.00n/a10
Jun ’24US$41.55
US$42.70
+2.8%
2.1%US$43.00US$40.00n/a10
May ’24US$39.38
US$41.30
+4.9%
18.1%US$55.00US$28.00n/a10
Apr ’24US$35.62
US$42.00
+17.9%
17.8%US$55.00US$28.00n/a10
Mar ’24US$40.06
US$42.30
+5.6%
18.3%US$55.00US$28.00n/a10
Feb ’24US$37.76
US$41.23
+9.2%
37.7%US$82.00US$25.00n/a11
Jan ’24US$36.68
US$41.05
+11.9%
37.9%US$82.00US$27.00n/a11
Dec ’23US$35.96
US$43.59
+21.2%
39.2%US$82.00US$27.00n/a11
Nov ’23US$50.67
US$66.82
+31.9%
14.6%US$82.00US$53.00n/a11
Oct ’23US$47.15
US$76.73
+62.7%
10.2%US$90.00US$68.00US$42.9811
Sep ’23US$59.57
US$79.00
+32.6%
9.8%US$90.00US$69.00US$42.7211
Aug ’23US$79.14
US$88.83
+12.2%
13.8%US$115.00US$68.00US$42.3612
Jul ’23US$71.57
US$90.75
+26.8%
14.9%US$115.00US$68.00US$42.1412
Jun ’23US$72.16
US$91.55
+26.9%
15.1%US$115.00US$68.00US$41.5511
May ’23US$73.09
US$94.10
+28.7%
15.4%US$115.00US$68.00US$39.3810
Apr ’23US$82.77
US$99.89
+20.7%
13.6%US$115.00US$68.00US$35.629
Mar ’23US$78.72
US$103.89
+32.0%
15.9%US$132.00US$68.00US$40.069

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.